Key result
Changes in diastolic strain basal time during doxorubicin are linked to subsequent cardiotoxicity.
Why the study?
Although diastolic dysfunction is common during cancer therapy, clear evidence that it predicts systolic dysfunction is lacking.
Does longitudinal diastolic strain time (Dst) predict doxorubicin-induced systolic dysfunction in patients with active breast cancer?
Cohort (n=69)
Does longitudinal diastolic strain time (Dst) predict doxorubicin-induced systolic dysfunction in patients with active breast cancer?
Changes in diastolic strain time during early doxorubicin therapy can predict subsequent subclinical systolic dysfunction in patients with breast cancer.
Answers are grounded in this paper and cite their sources.
Dst may aid early cardiotoxicity detection in breast cancer; leaves open prediction of systolic dysfunction pending validation.
Background: Although diastolic dysfunction is common among patients treated with cancer therapy, no clear evidence has been shown that it predicts systolic dysfunction. This study evaluated the correlation of longitudinal diastolic strain time (Dst) with the routine echocardiography diastolic parameters and to estimated its role in the early detection of cardiotoxicity among patients with active breast cancer. Methods: Data were collected as part of the Israel Cardio-Oncology Registry (ICOR), a prospective registry enrolling all adult patients referred to the cardio-oncology clinic. All patients with breast cancer, planned for Doxorubicin therapy were included. Echocardiography, including Global longitudinal systolic strain (GLS) and Dst, was assessed at baseline before chemotherapy (T1), during Doxorubicin therapy (T2) and after the completion of Doxorubicin therapy (T3). Cardiotoxicity were determined by GLS relative reduction of ≥15%. Dst was assessed as the time measured (ms) of the myocardium lengthening during diastole. =diastolic time (ms) measured. Results: Among 69 patients, 67 (97.1%) were females with a mean age 52±13years. Diastolic strain timeDst measurement was significantly associated with the standard routine diastolic parameters. Significant GLS reduction was observed in 10 (20%) patients at T3 . Both in a univariate and a multivariate analyses the change in Ds basal time from T1 to T2 emerged to be significantly associated with GLS reduction at T3 (p<0.04). Conclusions: Among breast cancer patients, Dst time showed high correlation to standard the routine diastolic echocardiography parameters. Relative reductionChange in Ds basal time emerged associated with clinically significant systolic dysfunction as measured by GLS reduction.
No takes yet. Share an insight, caveat, or question.
Hochstadt et al. (2020) conducted a cohort in active breast cancer (n=69). Change in diastolic strain basal time (Dst) was evaluated on Cardiotoxicity (GLS relative reduction of ≥15%) at T3 (p=<0.04). Change in diastolic strain basal time during Doxorubicin therapy was associated with subsequent cardiotoxicity in patients with breast cancer.
Synapse has enriched 8 closely related papers on similar clinical questions. Consider them for comparative context: